When: Price tags $315-320 and closes back above $322 with rising volume (2-day hold above 200 SMA confirms real support)

Then: Add 1/3 of target weight

HOLD: Maintain existing position, cap at 4% portfolio, no new capital. Wait for either a confirmed close above $340 with contracting MACD or a clean retest of the $310-$315 zone before adding.

• JPM's 13.2x forward P/E is at fair value, not a discount—five-year average is 12-13x, so buying at 13.2 is right at historical regime levels
• Technical posture shows distribution: lower highs since September 3rd, MACD below signal with histogram widening to negative 0.60, RSI sliding toward 30, VWAP at $335 vs spot $331
• Q3 earnings is a binary risk event, not a catalyst—the Q2 record quarter with 17.8% YoY revenue growth set an elevated bar; banks face downside risks from credit normalization, deposit cost stickiness, and trading revenue normalization
• JPM took a $4.4 billion special charge in Q2—litigation/regulatory charges don't disappear with favorable macro
• Net debt tripled from $65 billion to $223 billion in twelve months; trading securities grew by $157 billion in a single quarter, indicating dangerous leverage accumulation
• Buyback of ~4% of float annually is a ceiling on pain, not a floor under the stock—high-quality compounders with active buybacks still draw down 15-20% on guidance misses
• The aggressive analyst's own $318 stop-loss (~4% below current levels, near the 200-day MA) reveals his thesis lacks true asymmetric conviction
• Polymarket pricing at 96% for no cuts is a snapshot that can shift rapidly with one Fed meeting or CPI print
• JPM losing the Anthropic IPO mandate to Morgan Stanley signals structural competitive positioning weakness the bull case ignores

→ vs aggressive: The 13.2x forward P/E is not a 'gift'—it's right at the five-year historical average of 12-13x, and the stock only looks cheap in absolute terms, not relative to risk-adjusted earnings power

→ vs aggressive: 'Healthy digestion' framing ignores a clear distribution pattern: lower highs since Sept 3, MACD histogram at negative 0.60 widening downside, RSI toward 30, and VWAP at $335 with spot at $331 meaning average participant is underwater

→ vs aggressive: Q3 is the single biggest binary risk, not a catalyst—the record Q2 with 17.8% YoY revenue growth set an elevated bar, and the $4.4B special charge is a non-recurring drag that doesn't go away

→ vs aggressive: Net debt tripling from $65B to $223B in 12 months and trading securities growing $157B in one quarter means the 'fortress balance sheet' is accumulating risk, not reducing it

→ vs aggressive: The $318 stop-loss essentially at the 200-day MA reveals the aggressive analyst's own lack of conviction—true tailwind believers don't need a 4% downside exit

→ vs aggressive: Polymarket 96% no-cut pricing is a snapshot that can reprice instantly on one Fed meeting or CPI print, making the entire thesis fragile on a regime assumption

→ vs aggressive: Losing Anthropic IPO mandate to Morgan Stanley is a structural competitive positioning warning sign the bull case entirely ignores

Hold existing position with 318 stop; no new capital deployment until confirmed close above 340 with contracting MACD or clean retest of 310-315 zone; use Q3 earnings as resolution catalyst.

• 13.2x forward P/E is not a discount; JPM's 5-year average forward multiple sits around 12-13x, and banks trade at low multiples for structural reasons (leverage, cyclicality, regulatory overhang)
• 96% no-cut probability combined with 6% recession odds and accelerating NII represents a genuinely favorable macro setup
• Technical deterioration is real: lower highs since September 3rd, MACD below signal with widening histogram, RSI sliding toward oversold, VWMA at 335 vs spot at 331
• Lower-high sequence with negative momentum divergence represents distribution, not healthy digestion
• Long-term trend intact: 200 SMA at 319 holding, 10-year structural NII growth story intact, buyback bid is real
• Dimon succession overhang is overstated with no concrete signal of imminent transition
• Anthropic IPO mandate loss is noise (Polymarket volume only $12-22k), not meaningful competitive positioning signal
• Existing 4% portfolio cap is appropriate; treating the position as something to defend rather than hold is overthinking it
• Q3 earnings is a binary event with elevated expectations baked in that could resolve the technical ambiguity
• Pullback to 200 SMA (318) is a real possibility and prudent traders should respect that

→ vs aggressive: Fundamentals alone don't dictate entry timing; the 13.2x P/E is not a discount relative to JPM's 5-year average and structural bank multiple compression is permanent, not cyclical; consensus rate views in efficient markets tend to be correct

→ vs conservative: Succession overhang and Anthropic IPO mandate loss are overstated noise, not actionable risks; the stop at 318 at the 200 SMA strategic floor means existing positions should be held with conviction, not treated as liabilities to defend